CD19 CAR-T cells used for treatment of B cell lymphomas and leukemias upregulate suppressive receptors such as CTLA-4 and PD-1 which limit their activation and cytotoxicity. Here, PDCD1 is linked to B-cell non-Hodgkin lymphoma.